Literature DB >> 18425952

Interventions for strabismic amblyopia.

K Shotton1, S Elliott.   

Abstract

BACKGROUND: Amblyopia is reduced visual acuity in one or both eyes in the absence of any demonstrable abnormality of the visual pathway. It is not immediately resolved by the correction of refractive error. Strabismus develops in approximately 5% to 8% of the general population. The aim of treatment for amblyopia is to obtain the best possible level of vision in the amblyopic eye. Different treatment options were examined within the review.
OBJECTIVES: By reviewing available evidence we wanted to establish the most effective treatment for strabismic amblyopia. In particular this review aimed to examine the impact of conventional occlusion therapy for strabismic amblyopia and analyse the role of partial occlusion and optical penalisation for strabismic amblyopia. SEARCH STRATEGY: We searched CENTRAL, MEDLINE, EMBASE and LILACS in October 2007. There were no language or date restrictions in the electronic searches for trials. SELECTION CRITERIA: We included randomised controlled trials (RCTs) for the treatment of strabismic amblyopia including participants of any age. DATA COLLECTION AND ANALYSIS: Two authors working independently extracted and entered data into Review Manager 4.2 using the double data entry facility to check for errors. MAIN
RESULTS: We included two RCTs. The studies reported mean logMAR visual acuity achieved. Mean difference in visual acuity was calculated. When comparing conventional part-time occlusion (with any necessary glasses), PEDIG 2006 reported this treatment was more beneficial than glasses alone for strabismic amblyopia. Mean difference between groups was -0.18 (statistically significant 95% CI -0.32 to -0.04). Supplementing occlusion therapy with near activities may produce a better visual outcome compared to non-near activities after four weeks of treatment (PEDIG 2005). Mean difference between groups was -0.17 (95% CI -0.53 to 0.19). However, this data is from a pilot study and the full data set will be added to updates of the review when available. AUTHORS'
CONCLUSIONS: Occlusion, whilst wearing necessary refractive correction, appears to be more effective than refractive correction alone in the treatment of strabismic amblyopia. Combining occlusion and refractive correction with near activities may be more effective than occlusion and refractive correction alone. Further study of the role of near activities is necessary before a more definitive conclusion can be made. Results of a full trial are expected within the coming year. No RCTs were found that assessed the role of either partial occlusion or optical penalisation to refractive correction for strabismic amblyopia.

Entities:  

Mesh:

Year:  2008        PMID: 18425952     DOI: 10.1002/14651858.CD006461.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  6 in total

Review 1.  Amblyopia.

Authors:  Stephanie West; Cathy Williams
Journal:  BMJ Clin Evid       Date:  2011-06-30

2.  P-VEP as predictor of occlusion therapy.

Authors:  Satendra Singh; Shikha Gautam
Journal:  Korean J Ophthalmol       Date:  2009-06-09

Review 3.  The Role of the Amygdala in Facial Trustworthiness Processing: A Systematic Review and Meta-Analyses of fMRI Studies.

Authors:  Sara Santos; Inês Almeida; Bárbara Oliveiros; Miguel Castelo-Branco
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

Review 4.  Cost and quality of life of overlooked eye care needs of children.

Authors:  Monali S Malvankar-Mehta; Ryan Wilson; Erik Leci; Kelly Hatch; Sapna Sharan
Journal:  Risk Manag Healthc Policy       Date:  2018-02-23

5.  Efficacy of interventions for amblyopia: a systematic review and network meta-analysis.

Authors:  Yonghong Li; Huan Sun; Xiaojuan Zhu; Yana Su; Tianqi Yu; Xinyu Wu; Xiaoqin Zhou; Li Jing
Journal:  BMC Ophthalmol       Date:  2020-05-25       Impact factor: 2.209

Review 6.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Kate Shotton
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.